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 ARTICLE INFO   ABSTRACT 
 
 
Polymorphism analysis of pharmaceutical raw materials is considered one of the most relevant 
evaluations that should be done. As we know, different crystal forms from the same molecule have 
differences in terms of their physicochemical properties. According to the crystal form used, 
researchers can obtain benefits for the development of a new product or it can also imply a 
disadvantage for the formulation of the product. The present study focuses on the identification of 
crystalline forms in Rupatadine Fumarate raw material samples. The active pharmaceutical ingredient is 
an antihistaminic, classified as a second-generation selective H1 receptor, which shows advantages in 
terms of solubility in contrast with the free base and the trichloride form. Analytical techniques 
employed were: X ray diffraction, differential scanning calorimetry, thermogravimetric analysis, and 
infrared spectroscopy. The results were analyzed all together and compared with the information found 
in literature. Based on the results obtained, it was demonstrated that the analyzed drug samples don´t 
present any other polymorphic form besides A form, which is the only one reported in literature. 
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INTRODUCTION 
 
Polymorphism in crystalline solids is defined as any material 
with same chemical composition, but with a different  
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conformations. Diversity of crystalline forms from a 
pharmaceutical molecule of interest is based on a series of 
non-covalent interactions, which allow a better control of the 
chemical stability, dissolution profile, solubility and 
bioavailability of the API (Rodríguez, 2004). Nevertheless, it 
is well known that the most thermodynamically stable form of 
the molecule does not always represent the best option for the 
development of a new pharmaceutical product. The previous 
statement justifies the importance of knowing in detail the 
molecule and the different crystalline forms it may exhibit 
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according the conditions under which the production process is 
carried out (Rodríguez, 2004). Rupatadine fumarate (see 
Figure 1) is an API, its IUPAC nomenclature is 8
dihydro-11- [1- [(5-methyl-3-pyridyl) methyl] 
ylidene] -5H- benzo [5,6] cyclohepta [1,2
pyridine fumarate. [2, 3] 
 
 
Figure 1. Rupatadine fumarate chemical structure
 
The compound was first synthesized by a pharmaceutical 
company named J. Uriach& Cia, S.A in 2003. This API has a 
dual character, first it is considered a potent antihistaminic 
classified as second-generation selective H1 receptor, and also 
represents a platelet activating factor (PAF) antagonist. This 
pharmaceutical molecule is widely used in the symptomatic 
treatment of allergic rhinitis and urticaria in adults and 
children over 12 years of age, with a daily dose of 10 mg
Mingyu, 2014; Shangguan Qing, 2014; Aus
2008). The fumarate salt of Rupatadine gives advantages
terms of solubility and security when is compared with the free 
base form, as it decreases the side effects associated with the 
API. This molecule has some active metabolites, such as: 
desloratadine, 3-hydroxidesloratadine, 5-hydroxidesloratadine 
and 6-hydroxidesloratadine (Katiyar, 2008). 
compound is disclosed in Chinese patent CN 106188008 A, it 
only mentions the crystalline A form of Rupatadine fumarate. 
Given the above, it was necessary to study samples of 
pharmaceutical raw material of this compound for the 
identification of any other polymorphic forms that haven`t 
been identified. In order to determine modifications of the 
solid or crystalline state of the molecule, certain analytic 
techniques were involved (Niu Mingyu, 2014). 
technique is XDR, because this one determines directly 
differences in arrangement and conformation of the molecules. 
Also, TGA with DSC allows the identification of hydrates and 
solvates (He, 2009). Furthermore, vibrational spectroscopic 
techniques such as infrared are especially helpful for the 
characterization of polymorphs, because the patterns of 
hydrogen bonds vary between functional groups affected by 
the vibrations, what generates the characteristic signals for 
each polymorph (Rodríguez, 2004). 
 
MATERIALS AND METHODS 
 
Rupatadine fumarate raw material was produced by Enaltec
Laboratories, India, Lot No EL-03/L095/16025 and the 
samples were provided by a national industry. They were 
taken randomly and transferred to the test site under controlled 
conditions of temperature, light and humidity. The conditions 
and specifications of the equipment used are:
 
X ray Diffraction  
 
Equipment 
 
 Diffractometer: PANalytical Empyrean.
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Conditions 
 
 Temperature: room temperature
 Nickel filter. 
 Copper anode source Kα
 Polymethacrylate sample holder.
 Continuous analysis at 
3° to 40 ° 2θ. 
 Gas detector with photodiodes.
 Weight: 10 to 15 mg sample.
 Three replicas.  
 
Differential Scanning Calorimetry 
 
Equipment  
 
 DSC TA Instruments model Q200.
 
Conditions 
 
 Aluminum capsule. 
 100% Nitrogen Atmosphere 10 psi.
 Flow rate: 40 mL / minute.
 Heating series: isotherm at 20°C for 5 minutes, then 
increase 10 ° C / minute.
 Temperature range: 20 ° C to 250 ° C.
 Sensitivity Instrument and Recorder: Sensitivity 0.1 
uW. 
 Temperature precision: ± 0.05 °C.
 Temperature accuracy: ± 1 °C.
 Calorimetric precision: ± 0.1%.
 Calorimetric reproducibility: ± 0.1%.
 Weight: 4 to 5 mg sample.
 Calibration with Indium and distilled water. 
 Three replicas. 
 
Thermogravimetric Analysis 
 
Equipment 
 
 TGA TA Instruments model Q500.
 
Conditions 
 
 100% Nitrogen 10 psi Atmosphere.
 Volume flow: 40 mL / minute.
 Heating rate: 10 ° C / minute.
 Temperature range: 20 °C to 1000 °C.
  Weight: 4 to 5 mg sample.
 Sensitivity: 0.1 ug. 
 Isothermal temperature accuracy: ± 0.1%.
 Isothermal temperature 
 Three replicas. 
 
Infrared Spectroscopy  
 
Equipment 
 
 FTIR Thermo Scientific Nicolet model 6700.
 
Conditions 
 
 Range:  600 to 4000 cm
 Temperature: 25 °C. 
logy, Vol. 09, Issue, 02, pp.7482-7487, February
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precision ± 0.1%. 
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, 2018 
 Relative humidity: 30%. 
 200 scans per replica. 
 Three replicas. 
 
RESULTS 
 
The current investigation studies crystalline nature of 
Rupatadine fumarate pharmaceutical raw material, by making 
a comparison between the results obtained through different 
tests applied to the samples, and physicochemical parameters 
reported on literature and patents. Those results were used to 
make conclusions about the crystalline or amorphous state of 
the analyzed samples. Since there´s no pharmaceutical pattern 
of comparison for the crystalline form, the process of 
identification must be done according different techniques 
established in the United States Pharmacopeia (USP 39) for 
the determination of the physicochemical properties of interest
(United States Pharmapoeia Unidos, 2016). 
 
X ray Diffraction 
 
Figure 2 shows the results obtained through the
samples with X ray diffraction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The mentioned figure represents a classic pattern of a 
crystalline substance. The molecule of interest exhibits two 
principal peaks, the first one around 20 2θ and the second one 
is near 25 2θ. Even though, there are four other peaks of lower 
intensity around 13, 17, 21 and 23 2θ, they are still relevant for 
the characterization and identification of the crystalline form.
Figure 2. X ray diffractometry for Rupatadine fumarate raw material, Enaltec sample
Figure 3. DSC thermogram for Rupatadine fumarate raw material,
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 analysis of the 
 
Differential Scanning Calorimetry 
 
Figure 3 shows the results of the thermal analysis made to the 
samples of Rupatadine Fumarate raw mat
differential scanning calorimetry.
in Figure 3 shows an endothermic event at 201,28 ºC which 
corresponds to the melting point of the substance. Likewise, a 
decomposition of the sample is visible after the melting, an
is shown as a transition to an exothermic event around 208 ºC. 
The mentioned melting and decomposition occurs in a narrow 
range of temperature. There are no other thermal events related 
with any other decomposition, surface water loss or impurities 
before the melting point. 
 
Thermogravimetric Analysis 
 
Figure 4 shows the thermogravimetric analysis of Rupatadine 
Fumarate raw material from Enaltec Laboratories.
analyze the results, the thermogram shown in 
figure was divided in three stages: 1) 0 
°C and 3) 400 - 1000 °C. However, thermal events that take
place above 300 °C are not considered relevant for this 
analysis. There´s no mass decrease in the first stage, which can 
be interpreted as no loss of surfac
decomposition events in that temperature range.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It can also be explained by the lack of hydrates associated with 
the crystal. This situation is of great interest because the 
presence of crystallization waters in the samples is usually 
related to crystalline transitions. The explained behavior of the 
sample at this stage confirms what is shown by the 
thermogram of Figure 3. (Billah
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The analysis of the second stage showed about 20% of mass 
decrease between 205 °C - 208 °C, which matches with a first 
decomposition event of the API and it is also in agreement 
with the decomposition temperature obtained by differential 
scanning calorimetry analysis of the sample. Then, it is 
possible to appreciate a second and greater decomposition that 
takes place around 300 °C and causes the loss of more than 
75% of the sample. Finally, there´s a last decomposition event 
at 350 °C, which basically produces the loss of the remaining 
mass. It is relevant to say that the test allowed to evaluate and 
prove the sample´s purity, as there were any decomposition 
events or mass losses linked with residual solvents or related 
substances, present in raw material (Fitzpatrick, 2002 and 
Souza, 2013). 
 
Infrared Spectroscopy  
 
Figure 5 shows the main peaks identified for the API. The 
wave number at which the absorption bands are presented and 
the phenomena that occurs are detailed in the table at the end 
of the article. 
 
DISCUSSION 
 
The results obtained with each one of the executed tests were 
compared with the state of art found in the cited literature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therefore, the contrast was done according the following 
physicochemical parameters: Melting point, X ray diffraction 
pattern and IR pattern. 
 
XDR 
 
The X ray diffraction analysis of the sample didn´t reveal 
differences with the established in literature and is in 
agreement with what is presented in Figure 6. The 
diffractogram indicates the following characteristic peaks (2θ± 
0,2) for Rupatadine Fumarate form A (unique crystalline form 
reported): 13.6; 17.0; 21.3 and 23.1. However, Figure 6 shows 
another relevant peaks such as: 11.6; 12.5; 14.9; 15.5; 16.1; 
16.6; 18.1; 19.6; 20.2; 22.2; 23.6; 24.3; 24.8; 25.4; 25.8; 26.8; 
27.6; 28.5; 28.8; 30.6; 32.7; 33.2; 34.6; 36.2; 36.8 and 37.9 
(Mingyu, 2014 and Zhuhai Jin, 2016). 
 
DSC 
 
Literature establishes a melting point for Rupatadine fumarate 
around 197 - 201 °C. However, experimental reports indicate 
the beginning of this endothermic event at 194,8°C and its end 
point at 201,8°C. (Agarwal, 2007 and Carceller, 2017). It is 
possible to notice in the thermogram of Figure 3, that the 
melting point obtained through the sample´s analysis (199,08 - 
201,38°C) is within the range established in the state of art. 
(Uriach, 2017). 
 
 
Figure 4. Thermogravimetric analysis for Rupatadine Fumarate raw material, Enaltec sample 
 
 
 
Figure 5. Infrared spectroscopy analysis for Rupatadine Fumarate raw material, Enaltec sample 
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TGA 
 
This instrumental technique allows the study of thermal 
transitions in materials. Whenever a thermal event occurs it 
manifests itself as a mass change in the sample, as it can be 
observed in Figure 4. Since it is only possible to attribute mass 
changes to chemical reactions or water loss, the interpretation 
of these thermograms can tell us the temperature at which 
decomposition takes place, but not the melting of the 
substance (Haines, 1995). Even though there are no studies 
about thermal analysis of Rupatadine Fumarate by TGA, the 
realized test confirms the purity of raw material and also a first 
decomposition event. This was done by comparing the thermal 
events with the ones presented in the DSC thermogram. 
 
IR 
 
Figure 7 shows the IR spectrogram of API reported in 
literature. It is possible to distinguish the main peaks or bands 
from the previous spectrogram: 2922, 2897, 2550, 1700, 1653, 
1593, 1559, 1480, 1437, 1420, 1393, 1371, 1340, 1327, 1309, 
1281, 1164, 1105, 1095, 989, 972, 948, 874, 831, 818, 782, 
739 and 711 cm-1. Both, experimental analysis and literature, 
exhibit the presence of these peaks in characteristic zones of 
certain chemical groups present in API´s molecule (Niu 
Mingyu, 2014 and Agarwal, 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Literature reports the presence of characteristic absorptions 
related with stretching of C-H bonds of alkanes and aromatic 
compounds at 2982,02 cm-1. Likewise, peaks near of 1590 cm-
1 are characteristic of C=C bond stretching from aromatic 
rings. Absorption bands around 1685 cm-1 correspond to the 
presence of carbonyl groups (C=O) from the fumaric acid 
(Chavakula, 2013). Although there are some peaks considered 
characteristic for the substance like the ones close to 1160, 
1095 and 971 cm-1, they are unspecific in terms of chemical 
groups. On the other hand, bands around 839 and 781 cm-1 
represent stretching and vibration of C-Cl bonds (Agarwal, 
2007). 
 
Conclusions 
 
X ray diffraction test showed only the existence of Rupatadine 
fumarate crystalline form A. That fact is supported by the 
thermal analysis executed through differential scanning 
calorimetry, where an endotherm around 201 °C shows the 
melting point of the mentioned crystalline form, and it is also 
in agreement with what is established according to literature. 
Thermogravimetric assay didn´t present a mass decrease under 
the first decomposition event of the substance, which suggests 
the absence of solvents, impurities and crystal/surface water in 
the sample. Also, this test confirmed the link between the 
exotherm peak from DSC with the first decomposition event of 
 
 
Figure 6. Rupatadine fumarate diffractogram reported in literature (Zhuhai Jin, 2016). 
 
 
 
Figure 7. Rupatadine Fumarate infrared spectrogram reported in literature (Niu Mingyu, 2014 and Agarwal, 2007). 
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the API. Infrared spectroscopy analysis done to 
pharmaceutical raw material samples, showed characteristic 
bands of Rupatadine fumarate that are mentioned in literature. 
According to Figure 1 and in agreement with the experimental 
results and literature, it can be said that there´s a heterocyclic 
compound which counts with five rings, three of them 
aromatic and three with nitrogen as the only heteroatom. 
Furthermore, one of the aromatic rings presents a bond with a 
chlorine atom. Also, Figure 1 shows fumaric acid structure, 
what justifies the appearance of characteristic peaks related 
with carboxylic acids. Based on the results from the tests 
performed, the analyzed sample was identified as crystalline 
Rupatadine fumarate form A, which is also the only one 
reported in literature. Likewise, no other crystalline forms, 
neither surface water, residual solvents or impurities were 
found in the samples. 
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